<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Clin. Infect. Dis</journal-id><journal-id journal-id-type="publisher-id">cid</journal-id><journal-title-group><journal-title>Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America</journal-title></journal-title-group><issn pub-type="ppub">1058-4838</issn><issn pub-type="epub">1537-6591</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7108130</article-id><article-id pub-id-type="pmid">32150618</article-id><article-id pub-id-type="doi">10.1093/cid/ciaa237</article-id><article-id pub-id-type="publisher-id">ciaa237</article-id><article-categories><subj-group subj-group-type="heading"><subject>Major Article</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00290</subject></subj-group></article-categories><title-group><article-title>In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yao</surname><given-names>Xueting</given-names></name><xref ref-type="aff" rid="AF0001">1</xref><xref ref-type="author-notes" rid="fn-0001"/></contrib><contrib contrib-type="author"><name><surname>Ye</surname><given-names>Fei</given-names></name><xref ref-type="aff" rid="AF0002">2</xref><xref ref-type="author-notes" rid="fn-0001"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Miao</given-names></name><xref ref-type="aff" rid="AF0001">1</xref><xref ref-type="author-notes" rid="fn-0001"/></contrib><contrib contrib-type="author"><name><surname>Cui</surname><given-names>Cheng</given-names></name><xref ref-type="aff" rid="AF0001">1</xref><xref ref-type="author-notes" rid="fn-0001"/></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Baoying</given-names></name><xref ref-type="aff" rid="AF0002">2</xref><xref ref-type="author-notes" rid="fn-0001"/></contrib><contrib contrib-type="author"><name><surname>Niu</surname><given-names>Peihua</given-names></name><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Xu</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Dong</surname><given-names>Erdan</given-names></name><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Song</surname><given-names>Chunli</given-names></name><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Zhan</surname><given-names>Siyan</given-names></name><xref ref-type="aff" rid="AF0005">5</xref></contrib><contrib contrib-type="author"><name><surname>Lu</surname><given-names>Roujian</given-names></name><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Haiyan</given-names></name><xref ref-type="aff" rid="AF0001">1</xref><xref ref-type="aff" rid="AF0003">3</xref><xref ref-type="author-notes" rid="fn-0002"/></contrib><contrib contrib-type="author"><name><surname>Tan</surname><given-names>Wenjie</given-names></name><xref ref-type="aff" rid="AF0002">2</xref><xref ref-type="author-notes" rid="fn-0002"/></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Dongyang</given-names></name><xref ref-type="aff" rid="AF0001">1</xref><xref ref-type="author-notes" rid="fn-0002"/><xref ref-type="corresp" rid="c1"/><!--<email>liudongyang@sina.vip.com</email>--></contrib></contrib-group><aff id="AF0001"><label>1</label>
<institution>Drug Clinical Trial Center, Peking University Third Hospital,</institution> Beijing, <country country="CN">China</country></aff><aff id="AF0002"><label>2</label>
<institution>MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention,</institution>&#x000a0;<country country="CN">China</country> CDC, Beijing, <country country="CN">China</country></aff><aff id="AF0003"><label>3</label>
<institution>Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital,</institution> Beijing, <country country="CN">China</country></aff><aff id="AF0004"><label>4</label>
<institution>Department of Orthopedics, Peking University Third Hospital,</institution> Beijing, <country country="CN">China</country></aff><aff id="AF0005"><label>5</label>
<institution>Research Center of Clinical Epidemiology, Peking University Third Hospital,</institution> Beijing, <country country="CN">China</country></aff><author-notes><corresp id="c1">Corresponding author: Dongyang Liu, Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China. (<email>liudongyang@sina.vip.com</email>)</corresp><fn id="fn-0001"><p>Xueting Yao, Fei Ye, Miao Zhang, Cheng Cui and Baoyin Huang contributed equally</p></fn><fn id="fn-0002"><p>Dongyang Liu, Wenjie Tan and Haiyan Li contributed equally</p></fn></author-notes><pub-date pub-type="epub" iso-8601-date="2020-03-09"><day>09</day><month>3</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>09</day><month>3</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><elocation-id>ciaa237</elocation-id><history><date date-type="received"><day>25</day><month>2</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.</copyright-statement><copyright-year>2020</copyright-year><license license-type="cc-by" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="ciaa237.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) first broke out in Wuhan (China) and subsequently spread worldwide. Chloroquine has been sporadically used in treating SARS-CoV-2 infection. Hydroxychloroquine shares the same mechanism of action as chloroquine, but its more tolerable safety profile makes it the preferred drug to treat malaria and autoimmune conditions. We propose that the immunomodulatory effect of hydroxychloroquine also may be useful in controlling the cytokine storm that occurs late-phase in critically ill SARS-CoV-2 infected patients. Currently, there is no evidence to support the use of hydroxychloroquine in SARS-CoV-2 infection.</p></sec><sec id="s2"><title>Methods</title><p>The pharmacological activity of chloroquine and hydroxychloroquine was tested using SARS-CoV-2 infected Vero cells. Physiologically-based pharmacokinetic models (PBPK) were implemented for both drugs separately by integrating their <italic>in vitro</italic> data. Using the PBPK models, hydroxychloroquine concentrations in lung fluid were simulated under 5 different dosing regimens to explore the most effective regimen whilst considering the drug&#x02019;s safety profile.</p></sec><sec id="s3"><title>Results</title><p>Hydroxychloroquine (EC<sub>50</sub>=0.72 &#x003bc;M) was found to be more potent than chloroquine (EC<sub>50</sub>=5.47 &#x003bc;M) <italic>in vitro</italic>. Based on PBPK models results, a loading dose of 400 mg twice daily of hydroxychloroquine sulfate given orally, followed by a maintenance dose of 200 mg given twice daily for 4 days is recommended for SARS-CoV-2 infection, as it reached three times the potency of chloroquine phosphate when given 500 mg twice daily 5 days in advance.</p></sec><sec id="s4"><title>Conclusions</title><p>Hydroxychloroquine was found to be more potent than chloroquine to inhibit SARS-CoV-2 in vitro.</p></sec></abstract><kwd-group><kwd>Chloroquine</kwd><kwd>Hydroxychloroquine</kwd><kwd>SARS-CoV-2</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>article-lifecycle</meta-name><meta-value>PAP</meta-value></custom-meta><custom-meta><meta-name>edited-state</meta-name><meta-value>accepted-manuscript</meta-value></custom-meta></custom-meta-group></article-meta></front></article>